Glioblastoma multiforme (GBM) is the most frequently occurring primary malignant brain tumor; patients with GBM often have a very poor prognosis and differing responses to treatment. Therefore, it is very important to find new biomarkers that can predict clinical outcomes and help in treatment decisions. MicroRNAs are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and play a key role in the pathogenesis of GBM. In a group of 38 patients with primary GBM, we analyzed the expression of eight microRNAs (miR-21, miR-128a, miR-181c, miR-195, miR-196a, miR-196b, miR-221, and miR-222). In addition, we examined the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter by high-resolution melting analysis, as this has been shown to be a predictive marker in GBM. MGMT methylation status correlated with progression-free survival (P = 0.0201; log-rank test) as well as with overall survival (P = 0.0054; log-rank test). MiR-195 (P = 0.0124; log-rank test) and miR-196b (P = 0.0492; log-rank test) positively correlated with overall survival. Evaluation of miR-181c in combination with miR-21 predicted time to progression within 6 months of diagnosis with 92% sensitivity and 81% specificity (P < 0.0001). Our data confirmed that the methylation status of MGMT but also miR-21, miR-181c, miR-195, and miR-196b to be associated with survival of GBM patients. Above all, we suggest that the combination of miR-181c and miR-21 could be a very sensitive and specific test to identify patients at high risk of early progression after surgery.

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Zobrazit více v PubMed

Schwartzbaum JA, Fisher JL, Aldape KD et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2: 494–503; quiz 1 p following 16. PubMed

Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population‐based study. Cancer Res 2004; 64: 6892–9. PubMed

Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–96. PubMed

Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‐year analysis of the EORTC‐NCIC trial. Lancet Oncol 2009; 10: 459–66. PubMed

Esquela‐Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259–69. PubMed

Sana J, Hajduch M, Michalek J et al. MicroRNAs and glioblastoma: roles in core signaling pathways and potential clinical implications. J Cell Mol Med 2011; 15: 1636–44. PubMed PMC

Novakova J, Slaby O, Vyzula R et al. MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun 2009; 386: 1–5. PubMed

Slaby O, Lakomy R, Fadrus P et al. MicroRNA‐181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma 2010; 57: 264–9. PubMed

Ujifuku K, Mitsutake N, Takakura S et al. miR‐195, miR‐455‐3p and miR‐10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Cancer Lett 2010; 296: 241–8. PubMed

Guan Y, Mizoguchi M, Yoshimoto K et al. MiRNA‐196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res 2010; 16: 4289–97. PubMed

Hegi ME, Liu L, Herman JG et al. Correlation of O6‐methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008; 26: 4189–99. PubMed

Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192–7. PubMed

Sadones J, Michotte A, Veld P et al. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer 2009; 45: 146–53. PubMed

Blanc JL, Wager M, Guilhot J et al. Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 2004; 68: 275–83. PubMed

Wojdacz TK, Dobrovic A. Methylation‐sensitive high resolution melting (MS‐HRM): a new approach for sensitive and high‐throughput assessment of methylation. Nucleic Acids Res 2007; 35: e41. PubMed PMC

Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003. PubMed

Eoli M, Menghi F, Bruzzone MG et al. Methylation of O6‐methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival. Clin Cancer Res 2007; 13: 2606–13. PubMed

Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression‐free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743–50. PubMed

Wang X, Wang J, Ma H et al. Downregulation of miR‐195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol 2011; DOI: 10.1007/s12032‐011‐9880‐5 [Epub ahead of print]. PubMed

Xu T, Zhu Y, Xiong Y et al. MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009; 50: 113–21. PubMed

Liu L, Chen L, Xu Y et al. microRNA‐195 promotes apoptosis and suppresses tumorigenicity of human colorectal cancer cells. Biochem Biophys Res Commun 2010; 400: 236–40. PubMed

Soon PS, Tacon LJ, Gill AJ et al. miR‐195 and miR‐483‐5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res 2009; 15: 7684–92. PubMed

Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005; 334: 1351–8. PubMed

Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA‐21 targets a network of key tumor‐suppressive pathways in glioblastoma cells. Cancer Res 2008; 68: 8164–72. PubMed

Chen Y, Liu W, Chao T et al. MicroRNA‐21 down‐regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 2008; 272: 197–205. PubMed

Chan JA, Krichevsky AM, Kosik KS. MicroRNA‐21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029–33. PubMed

Srinivasan S, Patric IR, Somasundaram K. A ten‐microRNA expression signature predicts survival in glioblastoma. PLoS ONE 2011; 6: e17438. PubMed PMC

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

Real-World Evidence in Glioblastoma: Stupp's Regimen After a Decade

Identification of microRNAs differentially expressed in glioblastoma stem-like cells and their association with patient survival

MicroRNAs involved in chemo- and radioresistance of high-grade gliomas

MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients

Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells

Novel classes of non-coding RNAs and cancer